相关实验视频

Updated: May 1, 2026

Multi-target Parallel Processing Approach for Gene-to-structure Determination of the Influenza Polymerase PB2 Subunit

Multi-target Parallel Processing Approach for Gene-to-structure Determination of the Influenza Polymerase PB2 Subunit

Published on: June 28, 2013

致病性Interleukin-37b变种在体内优先考虑,以及用于高产可溶性生产的融合平台

Sana Tahir¹, Jannat Rahim¹, Saima Sadaf¹

¹School of Biochemistry and Biotechnology, University of the Punjab, Lahore, 54590, Pakistan.

|August 1, 2025

概括

这项研究确定了人体白蛋白-37异型1 (IL-37b) 中的致病性遗传变异,并开发了用于其可溶性生产的新型融合表达系统,推动了炎症性疾病的治疗开发.

科学领域:

生物化学生物化学
免疫学免疫学免疫学
计算生物学计算生物学

背景情况:

人类互白素-37异型1 (IL-37b) 是一种具有治疗前景的强效抗炎细胞因子.
临床应用受到疾病相关遗传变异的有限知识和可溶性蛋白质生产的挑战所阻碍.

研究的目的:

创建一个高可靠性,致病性IL-37b变体的目录.
建立基于聚变的表达平台,以高效地生产可溶性IL-37b.

主要方法:

使用多算法共识方法对3000多种IL-37b变体进行计算选.
在 silico 预测指导了融合合作伙伴 (富含亚斯巴酸盐的月素) 的选择,以表达.
优化表达和净化条件的融合蛋白在大肠杆菌.

主要成果:

确定了25种潜在的致病性非同义单核酸变体 (nsSNVs),其中16种预计会破坏IL-37b结构的稳定性并损害IL-18受体相互作用.
使用聚变系统实现了IL-37b的高可溶性表达 (~80%可溶性),在净化后产生167 mg/L.
与野生型IL-37b (<10%) 相比,显著提高了溶解度.

结论:

开发了致病性IL-37b变体的优先级目录,这对未来的功能研究至关重要.
建立了可溶性IL-37b的有效融合表达平台,克服了以前的生产限制.
综合计算和实验方法为IL-37b向治疗开发提供了基础.

关键词:

抗癌是一种抗癌.干细胞蛋白 37 干细胞蛋白 37 卢纳辛 (Lunasin) 是一种在月经中的药物.多算法共识方法多算法共识方法.病原性变体的病原性变体可溶性表达的可溶性表达

更多相关视频

A Comparative Approach to Characterize the Landscape of Host-Pathogen Protein-Protein Interactions

A Comparative Approach to Characterize the Landscape of Host-Pathogen Protein-Protein Interactions

Published on: July 18, 2013

Development of Recombinant Proteins to Treat Chronic Pain

Development of Recombinant Proteins to Treat Chronic Pain

Published on: April 11, 2018

相关概念视频

Upstream Processing

Upstream Processing

Upstream processing represents a critical phase in biomanufacturing, wherein biological systems such as microorganisms, mammalian cells, or insect cells are cultivated to produce therapeutic proteins, vaccines, enzymes, or other biologically derived products. This phase encompasses all steps from the selection and genetic manipulation of the production organism to the cultivation of cells in bioreactors under tightly controlled environmental conditions.Host Selection and Genetic OptimizationThe...

Production of Pharmaceuticals

Production of Pharmaceuticals

Industrial insulin production uses genetically engineered E. coli expressing a proinsulin gene controlled by a tryptophan promoter and containing a methionine linker for later cleavage. The cells also carry ampicillin resistance for selective growth. Seed cultures are stored at −80 °C and production begins by thawing a small amount to inoculate starter cultures, which are progressively scaled to a 50,000-L bioreactor. In the bioreactor, E. coli grow in nutrient-rich media under...